Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3174 Utility and timing of Technetium-99m-diethylene-triamine-penta-acetic acid measurement of glomerular filtration rate in patients undergoing peptide receptor radionuclide therapy

Introduction: Renal toxicity is a potential side effect of Lutetium-177 Peptide Receptor Radionuclide Therapy (177Lu-PRRT). Some centres use serial Technetium-99m-diethylene-triaminepentaacetic acid (99mTc-DTPA) glomerular filtration rate (GFR) measurements to detect early renal toxicity, but there is no consensus regarding the timing of serial scans nor its utility.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Agarwal V, Gordon S, Bailey D, Pavlakis N, Aslani A,

Keywords: Technetium-99m-diethylene-triaminepentaacetic acid (99mTc-DTPA) glomerular filtration rate (GFR), Lutetium-177 Peptide Receptor Radionuclide Therapy (177Lu-PRRT),

#1787 Towards Personalizing PRRT with [177Lu]-Dotatate to Minimise Renal Toxicity in Neuroendocrine Tumour Patients

Introduction: The kidney is a dose-limiting organ in [177Lu]-Dotatate PRRT (Lutate) and thus renal function is an important prescribing consideration for NET patients. The effect of baseline renal function on kidney absorbed dose is unclear.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Eslick E, Hayes A, Willowson K, Ryu H, Hennessy T,

Keywords: peptide receptor radionuclide therapy, Lutate, renal function, kidney absorbed dose,

#1388 Nephrotoxicity after PRRT with 177Lu-DOTA-Octreotate

Introduction: Renal toxicity may occur after Peptide Receptor Radionuclide Therapy (PRRT). Risk factors have been identified for renal toxicity after 90Y based PRRT.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Bergsma H

Authors: Bergsma H, Konijnenberg M, Van der Zwan W, Kam B, Teunissen J,

Keywords: PRRT, Kidneys, Toxicity, Dosimetry,

#1098 177Lu Dotatate vs Sequential 177Lu Dotatate and 90Y Dotatate: Treatment Outcomes for PRRT Patients at the Christie - A Clinical Audit

Introduction: The traditional treatment regime of somatostatin receptor positive NETs by molecular radiotherapy was based on single radionuclides (e.g. 90Y Dotatate or 177Lu Dotatate), delivered as multiple cycles to allow normal tissue recovery. However a newer practice of alternating tcycles of 177Lu and Y90 Dotatate was implemented at the Christie following introduction of this regime in some European centres. Subsequent follow up studies have indicated that longer overall survival and reduced loss of kidney function is found in patient cohorts treated with combined 177Lu and 90Y regimes to either 177Lu or 90Y alone.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Tipping J

Authors: Page E, Tipping J, Birch E, Hamilton D, Manoharan P,

Keywords: PRRT, Toxicity, Audit, RM Dose,

#900 Renal Effects of Streptozocin: Preliminary Results of the STREPTOTOX Study

Introduction: Based on old studies, Streptozocin (STZ) is known to have some renal toxicity.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Mitry E

Authors: Mitry E, Brixi H, Lecomte T, Lombard-Bohas C, Seitz J,

Keywords: digestive neuroendocrine tumors, streptozotocin, nephrotoxicity, chemotherapy,